RETRACTED ARTICLE:SPHK1 inhibitor suppresses cell proliferation and invasion associated with the inhibition of NF-?B pathway in hepatocellular carcinoma

Tumor Biology

Volumn 36, Issue 3, 2014, Pages 1503-1509

  Zhang, Zijie ^a   Yan, Zhenyu ^a   Yuan, Zheng ^a   Sun, Yanzhen ^a   He, Haifa ^a   Mai, Chunyang ^a  

^a The Central Hospital of Nanyang   (China)

Author keywords

DMS; Hepatocellular carcinoma; Microvessel density; Sphingosine kinase1; Targeted therapy

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N,N-DIMETHYLSPHINGOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; SPHINGOSINE; SPHINGOSINE KINASE;

ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; CELL LINE; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; HEPG2 CELL LINE; HUMAN; LIVER NEOPLASMS; METABOLISM; NEOPLASM INVASIVENESS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CARCINOMA, HEPATOCELLULAR; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; NEOPLASM INVASIVENESS; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); SIGNAL TRANSDUCTION; SPHINGOSINE;

EID: 84930900389     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2665-7     Document Type: TB

References (15)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
2. Ades S. Adjuvant chemotherapy for colon cancer in the elderly: moving from evidence to practice. Oncology (Williston Park). 2009;23(2):162–7.
3. Frangov T, Gaĭdarski R, Dimitrova V, Popov V, Grozeva K, Rusenov D. [Prognostic factors for survival in primary liver cancer]. Khirurgiia (Sofiia). 2007;(6):36–9.
4. Song L, Xiong H, Li J, Liao W, Wang L, Wu J, et al. Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-κB pathway in human non-small cell lung cancer. Clin Cancer Res. 2011;17(7):1839–49.
5. Pitson SM, Powell JA, Bonder CS. Regulation of sphingosine kinase in hematological malignancies and other cancers. Anticancer Agents Med Chem. 2011;11(9):799–809.
6. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene. 2003;22:5093–107.
7. Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, et al. Adecade’s studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:187–96.
8. Yang Y, Nagano H, Ota H, Morimoto O, Nakamura M, Wada H, et al. Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery. 2007;141:196–202.
9. Nava VE, Hobson JP, Murthy S, Milstien S, Spiegel S. Sphingosine kinase type 1 promote sestrogen-dependent tumori-genesis of breast cancer MCF-7 cells. Exp Cell Res. 2002;281:115127.
10. Kapitonov D, Allegood JC, Mitchell C, Hait NC, Almenara JA, Adams JK, et al. Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. Cancer Res. 2009;69:6915–23.
11. Pchejetski D, Doumerc N, Golzio M, Naymark M, Teissi J, Kohama T, et al. Chemo-sensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Mol Cancer Ther. 2008;7:1836–45.
12. Schwartz GK, Ward D, Saltz L, et al. Apilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and incombination with doxorubicin. Clin Cancer Res. 1997;3:537–43.
13. Nava VE, Cuvillier O, Edsall LC, et al. Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells. Cancer Res. 2000;60:4468–74.
14. Liu H, Sugiura M, Nava VE, et al. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J Biol Chem. 2000;275:19513–20.
15. 2+ concentration in human cancer cells. Int J Mol Med. 2014;33:17–24.